Comparative Pharmacology
Head-to-head clinical analysis: RETEVMO versus SORAFENIB TOSYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RETEVMO versus SORAFENIB TOSYLATE.
RETEVMO vs SORAFENIB TOSYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
Sorafenib is a multikinase inhibitor that inhibits Raf serine/threonine kinases (C-Raf, B-Raf, and mutant B-Raf), vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptor (PDGFR-β), and other kinases, thereby inhibiting tumor cell proliferation and angiogenesis.
160 mg orally twice daily
400 mg orally twice daily on an empty stomach (at least 1 hour before or 2 hours after a meal).
None Documented
None Documented
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
Terminal half-life of sorafenib is approximately 25-48 hours (mean ~37 hours); clinical steady-state achieved within 7 days.
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Fecal (77%) as unchanged drug and metabolites; renal (19%) as glucuronide conjugates; <1% excreted unchanged in urine.
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor